22 related articles for article (PubMed ID: 38567478)
1. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
[TBL] [Abstract][Full Text] [Related]
2. Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.
Chevrier M; Bobbala D; Villalobos-Hernandez A; Khan MG; Ramanathan S; Saucier C; Ferbeyre G; Geha S; Ilangumaran S
BMC Cancer; 2017 Feb; 17(1):157. PubMed ID: 28235401
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms.
Yaman O; Ozdiler E; Orhan D; Sak SD; Baltaci S; Tulunay O; Göğüş O
Urol Int; 1997; 58(4):199-202. PubMed ID: 9253117
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate carcinoma.
Petrescu A; Mârzan L; Codreanu O; Niculescu L
Rom J Morphol Embryol; 2006; 47(2):143-6. PubMed ID: 17106522
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of p53 alterations in surgically treated prostate cancers.
Schlomm T; Iwers L; Kirstein P; Jessen B; Köllermann J; Minner S; Passow-Drolet A; Mirlacher M; Milde-Langosch K; Graefen M; Haese A; Steuber T; Simon R; Huland H; Sauter G; Erbersdobler A
Mod Pathol; 2008 Nov; 21(11):1371-8. PubMed ID: 18552821
[TBL] [Abstract][Full Text] [Related]
6. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
7. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer.
Uzoaru I; Rubenstein M; Mirochnik Y; Slobodskoy L; Shaw M; Guinan P
J Surg Oncol; 1998 Jan; 67(1):33-7. PubMed ID: 9457254
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of tumor suppressor protein p53 in prostate cancer.
Ben Rejeb S; Kouki N; Elfekih S; Cherif I; Khouni H
Tunis Med; 2024 Feb; 102(2):111-115. PubMed ID: 38567478
[TBL] [Abstract][Full Text] [Related]
10. [Recent advances on molecular pathology of prostate carcinoma].
Niu HL; Tao Y
Ai Zheng; 2003 May; 22(5):552-6. PubMed ID: 12753724
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
